The clinical efficacy and the tolerability of (-)-moprolol and of the racemic derivative (±)-moprolol were studied in twenty mild or moderate hypertensive patients in a double-blind cross-over trial. Both the compounds significantly reduced blood pressure, but only (-)-moprolol reduced heart rate. (-)-Moprolol induced a reduction in cardiac output, whereas (±)-moprolol did not change cardiac output, but significantly reduced total peripheral resistance. Both the drugs improved significantly the tolerance to exercise. (-)-Moprolol did not induce any significant side effect, whereas (±)-moprolol caused headache or dizziness in five patients.
|Number of pages||8|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1984|
ASJC Scopus subject areas